You searched for "gene therapy"
Systemic rituximab immunotherapy in the management of primary ocular adnexal lymphoma single institutional experience
Ocular adnexal lymphomas constitute 2% of all non-Hodgkin’s disease and 5-15% of all extranodal lymphomas and are usually localised, low-grade and of B-cell origin. This opens them up to potential treatment with a systemic monoclonal antibody-based drug (rituximab) directed at...
Microbiology, risk factors and outcomes of microbial keratitis in Sydney, Australia
The authors present a retrospective case series including all patients with microbial keratitis and ocular surface diseases (OSD), including dry eye, blepharitis, Stevens-Johnson syndrome and / or ocular cicatricial pemphigoid, over a five-year period between 2012 and 2016. A total...
Lacrimal drainage system malignancies
This retrospective case series looks at the rare cases of lacrimal drainage system malignancies. The authors have identified 14 patients in 24 years, at a tertiary referral centre in the Indian subcontinent. Many previous publications have found squamous cell carcinoma...
Outcomes of chemo versus no therapy for optic pathway glioma in NF1
The aim of this study was to evaluate the visual outcomes of a cohort of children with optic pathway gliomas and neurofibromatosis type 1 (NF1), with comparison of children treated with chemotherapy or not. This was a retrospective study of...
Lacrimal gland carcinoma outcomes
This is retrospective review of outcomes of lacrimal gland epithelial tumours treated between 1972 and 2014 at Moorfields Eye Hospital. Seventy-nine patients were reported, comprising 53 adenoid cystic carcinomas, 15 primary adenocarcinomas and 11 carcinomas ex-pleomorphic adenoma. The authors compare...
Adjunctive topical 5-FU vs. MMC for surgically excised, localised OSSN
Ocular surface squamous neoplasia (OSSN) comprises a range of dysplasia including corneal-conjunctival intraepithelial neoplasia and invasive squamous cell carcinoma. The traditional treatment for localised non-invasive OSSN has been surgical excision with or without intraoperative cryotherapy. Postoperative adjunctive topical chemotherapy significantly...
Melphalon treatment of retinoblastoma
The purpose of this study was to report the authors’ experience with superselective ophthalmic artery infusion of Melphalon (SOAIM) for the treatment of five cases of unilateral sporadic retinoblastoma involving the macula. Standard therapy included a cycle of three infusions...
RPE tears in cases of IPCV
The aim of this study was to investigate the occurrence, characteristics, management and prognosis of retinal pigment epithelium (RPE) tears in patients with polypoidal choroidal vasculopathy (PCV). Medical records of previous cases were reviewed over an eight-year period from a...
Subthreshold micropulse laser in BRVO
The purpose of this retrospective, consecutive, single-centre, non-randomised, and case-control study was to verify the therapeutic effects and safety of oedema (from branch retinal vein occlusion (BRVO)) recurrence suppression effect using 577-nm subthreshold micropulse laser photocoagulation (SMLP) in combination with...
Macular atrophy with aflibercept
The authors of this paper set out to investigate the prevalence of macular atrophy in treatment-naive patients with neovascular AMD undergoing aflibercept monotherapy (three monthly loading injections followed by subsequent treatment every two months). Case notes over a three year...
Reduction of severe visual loss and complications following IAC for RB
This was a retrospective cohort study of patients with retinoblastoma (RB) who required intra-arterial chemotherapy (IAC) between 2013 and 2015, who had relapsed following systemic chemotherapy. A total of nine patients were included in the study and their ocular complications...
